GlassScriptPhysician profile
Sau Yan Yee
NPI 1740288570
$4,256.11
in general payments reported to CMS, 2019-2025
27 companies · $807 in 2025
The $807 reported for 2025 was more than what 95% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $226 · 2021: $376 · 2022: $488 · 2023: $1,128 · 2024: $1,067 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,959 · Education: $42.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.21 |
| Education | $42.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,249.69 | 2020-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $463.86 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $398.33 | 2022-2025 | Arexvy, Shingrix, Rotarix |
| Astrazeneca Pharmaceuticals LP | $338.75 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $308.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $274.21 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Optos, INC. | $226.14 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.48 | 2021-2024 | Trulance, Xifaxan |
| Pfizer INC. | $127.78 | 2021-2025 | |
| Exact Sciences Corporation | $100.61 | 2023-2025 | Cologuard Collection Kit |
| Cranial Technologies, INC | $82.32 | 2019-2025 | Doc Band |
| Allergan, INC. | $81.45 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $71.52 | 2019-2021 | |
| Genentech USA, INC. | $55.35 | 2019-2022 | |
| Lundbeck LLC | $48.38 | 2024-2025 | Vyepti |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $42.43 | 2019-2022 | |
| Amarin Pharma, INC. | $41.46 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.33 | 2025 | |
| Astellas Pharma US INC | $38.36 | 2024-2025 | Veozah |
| Dexcom, INC. | $22.26 | 2025 | Dexcom G6 Transmitter |
| Mckesson Medical-Surgical, INC. | $20.00 | 2021 | |
| Abbvie INC. | $17.86 | 2024 | |
| Mannkind Corporation | $17.49 | 2024 | |
| Sanofi-Aventis U.S. LLC | $16.78 | 2025 | |
| Merck Sharp & Dohme LLC | $14.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $13.85 | 2021 | |
| Daiichi Sankyo INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sau Yee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.